Literature DB >> 25516915

Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.

Areef Ishani1, Jiannong Liu2, James B Wetmore2, Kimberly A Lowe3, Thy Do3, Brian D Bradbury3, Geoffrey A Block4, Allan J Collins2.   

Abstract

BACKGROUND AND OBJECTIVES: Patients receiving dialysis undergo parathyroidectomy to improve laboratory parameters in resistant hyperparathyroidism with the assumption that clinical outcomes will also improve. However, no randomized clinical trial data demonstrate the benefits of parathyroidectomy. This study aimed to evaluate clinical outcomes up to 1 year after parathyroidectomy in a nationwide sample of patients receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using data from the US Renal Data System, this study identified prevalent hemodialysis patients aged ≥18 years with Medicare as primary payers who underwent parathyroidectomy from 2007 to 2009. Baseline characteristics and comorbid conditions were assessed in the year preceding parathyroidectomy; clinical events were identified in the year preceding and the year after parathyroidectomy. After parathyroidectomy, patients were censored at death, loss of Medicare coverage, kidney transplant, change in dialysis modality, or 365 days. This study estimated cause-specific event rates for both periods and rate ratios comparing event rates in the postparathyroidectomy versus preparathyroidectomy periods.
RESULTS: Of 4435 patients who underwent parathyroidectomy, 2.0% died during the parathyroidectomy hospitalization and the 30 days after discharge. During the 30 days after discharge, 23.8% of patients were rehospitalized; 29.3% of these patients required intensive care. In the year after parathyroidectomy, hospitalizations were higher by 39%, hospital days by 58%, intensive care unit admissions by 69%, and emergency room/observation visits requiring hypocalcemia treatment by 20-fold compared with the preceding year. Cause-specific hospitalizations were higher for acute myocardial infarction (rate ratio, 1.98; 95% confidence interval, 1.60 to 2.46) and dysrhythmia (rate ratio 1.4; 95% confidence interval1.16 to 1.78); fracture rates did not differ (rate ratio 0.82; 95% confidence interval 0.6 to 1.1).
CONCLUSIONS: Parathyroidectomy is associated with significant morbidity in the 30 days after hospital discharge and in the year after the procedure. Awareness of clinical events will assist in developing evidence-based risk/benefit determinations for the indication for parathyroidectomy.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  hemodialysis; hyperparathyroidism; mortality

Mesh:

Substances:

Year:  2014        PMID: 25516915      PMCID: PMC4284409          DOI: 10.2215/CJN.03520414

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  25 in total

1.  Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies.

Authors:  G Gasparri; M Camandona; G C Abbona; M Papotti; A Jeantet; E Radice; B Mullineris; M Dei Poli
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

2.  Outcomes after thyroidectomy and parathyroidectomy.

Authors:  Prateek K Gupta; Russell B Smith; Himani Gupta; R Armour Forse; Xiang Fang; William M Lydiatt
Journal:  Head Neck       Date:  2011-06-02       Impact factor: 3.147

3.  Improved long-term survival of dialysis patients after near-total parathyroidectomy.

Authors:  Jyotirmay Sharma; Paolo Raggi; Nancy Kutner; James Bailey; Rebecca Zhang; Yijian Huang; Charles A Herzog; Collin Weber
Journal:  J Am Coll Surg       Date:  2012-04       Impact factor: 6.113

4.  Vintage, nutritional status, and survival in hemodialysis patients.

Authors:  G M Chertow; K L Johansen; N Lew; J M Lazarus; E G Lowrie
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

5.  Parathyroidectomy: whom and when?

Authors:  Rosa Jofré; Juan Manuel López Gómez; Javier Menárguez; José Ramón Polo; Martin Guinsburg; Teresa Villaverde; Isabel Pérez Flores; Diana Carretero; Patrocinio Rodríguez Benitez; Rafael Pérez García
Journal:  Kidney Int Suppl       Date:  2003-06       Impact factor: 10.545

6.  Results of surgical treatment of renal hyperparathyroidism.

Authors:  E Neonakis; M H Wheeler; H Krishnan; G A Coles; F Davies; J S Woodhead
Journal:  Arch Surg       Date:  1995-06

7.  Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.

Authors:  Rajeev Narayan; Robert M Perkins; Elizabeth P Berbano; Christina M Yuan; Robert T Neff; Eric S Sawyers; Fred E Yeo; Gwenaelle M Vidal-Trecan; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2007-06       Impact factor: 8.860

8.  Fracture risk after parathyroidectomy among chronic hemodialysis patients.

Authors:  Kyle D Rudser; Ian H de Boer; Annemarie Dooley; Bessie Young; Bryan Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2007-07-18       Impact factor: 10.121

9.  Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism.

Authors:  Andrea Trombetti; Catherine Stoermann; John H Robert; François R Herrmann; Pietra Pennisi; Pierre-Yves Martin; René Rizzoli
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Healthcare use and costs before and after parathyroidectomy in patients on dialysis.

Authors:  Vasily Belozeroff; Kerry Cooper; Gregory Hess; Chun-Lan Chang
Journal:  BMC Health Serv Res       Date:  2013-07-02       Impact factor: 2.655

View more
  41 in total

1.  The Authors Reply.

Authors:  Hirotaka Komaba; Masatomo Taniguchi; Atsushi Wada; Kunitoshi Iseki; Yoshiharu Tsubakihara; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2015-09       Impact factor: 10.612

2.  Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Authors:  Irfana H Soomro; David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

3.  Removing the problem: parathyroidectomy for calciphylaxis.

Authors:  Mohamed Hassanein; Heather Laird-Fick; Richa Tikaria; Saleh Aldasouqi
Journal:  BMJ Case Rep       Date:  2018-12-22

4.  Parathyroidectomy: Complex Decisions about a Complex Procedure.

Authors:  James B Wetmore
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-06       Impact factor: 8.237

Review 5.  [Management of secondary hyperparathyroidism-current impact of parathyroidectomy].

Authors:  Emanuel Zitt; Karl Lhotta
Journal:  Wien Med Wochenschr       Date:  2016-02-25

6.  Increasing Age Hinders the Decline in B-Type Natriuretic Peptide Following Parathyroidectomy in Dialysis Patients.

Authors:  Tun-Pang Chu; Po-Sheng Yang; Jie-Jen Lee; Chih-Jen Wu; Shih-Ping Cheng
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

7.  Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis.

Authors:  Rocco Ferrandino; Scott Roof; Yue Ma; Lili Chan; Priti Poojary; Aparna Saha; Kinsuk Chauhan; Steven G Coca; Girish N Nadkarni; Marita S Teng
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-26       Impact factor: 3.497

8.  CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy.

Authors:  Antonio Bellasi; Luigi Morrone; Maria Cristina Mereu; Carlo Massimetti; Elena Pelizzaro; Giuseppe Cianciolo; Marzia Pasquali; Vincenzo Panuccio
Journal:  J Nephrol       Date:  2018-03-07       Impact factor: 3.902

Review 9.  Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Authors:  Wei Ling Lau; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

Review 10.  Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.